by The U.S. hemophilia treatment market is primarily engaged in manufacturing recombinants coagulation factor concentrates, plasma derived concentrates, desmopressin, and anti-inhibitors for treating hemophilia A and B. Recombinant concentrates accounts for major share due to advantages such as enhanced safety, less infection risks, increased efficacy, and reduced side-effects compared to plasma-derived concentrates. Furthermore, availability of extended half-life or long-acting products enables lower dosing frequency resulting in improved adherence to treatment and quality of life for patients. Hemophilia treatment ensures prevention and control of bleeding episodes by replenishing missing clotting factors in the blood which are absent or deficient in hemophilic patients.
The Global U.S. Hemophilia Treatment Market Size is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the U.S. hemophilia treatment are Takeda Pharmaceutical Company Limited, Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc. and Among Others. Key players are mainly focused on R&D of gene therapy and long-acting products to provide more efficacious treatment options.
The growing prevalence of hemophilia A and B disorders along with rising healthcare expenditure is driving the demand for hemophilia treatment products in the U.S. market. According to CDC, around 20,000 people are diagnosed with hemophilia in the U.S. Availability of high cost extended half-life products is also contributing to market growth.
U.S. market players are expanding their geographic presence globally through collaboration and partnership with international pharma companies. For instance, Sanofi has launched long-acting hemophilia treatment Eloctate in countries across Middle East and North Africa region.
Market Key Trends
Gene therapy is emerging as a promising treatment trend for hemophilia with potential of a single dose cure. Companies are conducting extensive research to develop safe, efficacious and affordable gene therapy to provide functional cure. In 2021, BioMarin received FDA approval for first gene therapy Valrox (Valoctocogene Roxaparvovec) indicated for severe hemophilia A. Such approvals mark beginning of new chapter for long term sustainable treatment of hemophilia.
Porter’s Analysis
Threat Of New Entrants: Limited threat as high investment cost and strong regulations required to enter hemophilia treatment market in US.
Bargaining Power Of Buyers: Moderate bargaining power as hemophilia treatment has limited substitutes however demand for low cost biosimilars and generics is increasing.
Bargaining Power Of Suppliers: Strong bargaining power as limited number of key biopharmaceutical companies dominate US hemophilia treatment market.
Threat Of New Substitutes: Low threat as no other therapeutic approach has proven as effective as recombinant factor replacement therapy for hemophilia.
Competitive Rivalry: High rivalry among major players to gain market share and maintain leadership through new product launches.
Geographical Regions
The US dominates the global hemophilia treatment market in terms of value as North America accounts for over 40% market share currently due to developed healthcare infrastructure and high treatment cost in the country.
Asia Pacific is poised to emerge as the fastest growing regional market during the forecast period at a CAGR of around 7% on back of rising demand, increasing healthcare expenditure and presence of less stringent regulations in many Asia Pacific countries compared to the US.
What Are The Key Data Covered In This U.S. Hemophilia Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the U.S. Hemophilia Treatment’s growth between 2024 and 2031.
:- Accurate calculation of the size of the U.S. Hemophilia Treatment and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- U.S. Hemophilia Treatment Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of U.S. Hemophilia Treatment vendors
FAQ’s
Q.1 What are the main factors influencing the U.S. Hemophilia Treatment?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top U.S. Hemophilia Treatment companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the U.S. Hemophilia Treatment’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
